<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39372698</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1937-8688</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>The Pan African medical journal</Title><ISOAbbreviation>Pan Afr Med J</ISOAbbreviation></Journal><ArticleTitle>[Livedo reticularis following administration of COVID-19 vaccine: a case report].</ArticleTitle><Pagination><StartPage>9</StartPage><MedlinePgn>9</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.11604/pamj.2024.49.9.31779</ELocationID><Abstract><AbstractText>The emergence of severe acute respiratory syndrome coronavirus 2 has made it crucial to develop safe vaccines. Three main types of vaccines are currently available. Although they have proven to be very secure, they have caused various adverse effects. We here report a rare case of livedo reticularis following the administration of COVID-19 vaccine in a 54-year-old woman. It occurred 24 hours after vaccination, accompanied by respiratory, digestive, and neurological disorders and deterioration in general condition. Examinations revealed skin lesions compatible with livedo reticularis, mild inflammatory syndrome and hypercholesterolemia. Imaging showed no abnormalities. Immunological tests were positive for lupus anticoagulant. The patient received symptomatic treatment, with improvement in neurological and joint symptoms and a slight regression of skin rashes. After three months, the lupus anticoagulant test remained positive, confirming post-vaccination antiphospholipid syndrome (APS). The association of livedo reticularis with COVID-19 vaccine should not be underestimated and its degree of severity remains to be determined. More data and cases need to be collected for a more in-depth and detailed analysis.</AbstractText><CopyrightInformation>Copyright: Meryem Ouhaddach et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ouhaddach</LastName><ForeName>Meryem</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service de Médecine Interne, Hôpital Arrazi CHU Mohamed VI, Marrakech, Maroc.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zahlane</LastName><ForeName>Mouna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service de Médecine Interne, Hôpital Arrazi CHU Mohamed VI, Marrakech, Maroc.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Essaadouni</LastName><ForeName>Lamiaâ</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Service de Médecine Interne, Hôpital Arrazi CHU Mohamed VI, Marrakech, Maroc.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Livédo réticulaire post vaccin anti COVID-19: à propos d’un cas.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Uganda</Country><MedlineTA>Pan Afr Med J</MedlineTA><NlmUniqueID>101517926</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016682">Lupus Coagulation Inhibitor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054068" MajorTopicYN="Y">Livedo Reticularis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016682" MajorTopicYN="N">Lupus Coagulation Inhibitor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="fre"><AbstractText>L'apparition du syndrome respiratoire aigu sévère coronavirus 2 a rendu crucial le développement de vaccins sûrs, dont trois principaux types existent à ce jour. Bien qu'ils aient montré une excellente sécurité, ils ont provoqué divers effets indésirables. Nous présentons un cas rare de livédo réticulaire post-vaccinal chez une femme de 54 ans, apparu 24 heures après la vaccination, accompagné de troubles respiratoires, digestifs et neurologiques, et d'une altération de l'état général. Les examens ont révélé des lésions cutanées compatibles avec un livédo réticulaire, un syndrome inflammatoire léger, et une hypercholestérolémie. L´imagerie était sans particularité. Un bilan immunologique a montré un anticoagulant lupique positif. La patiente a été traitée symptomatiquement, avec une amélioration des symptômes neurologiques et articulaires, et une légère régression des éruptions cutanées. Après trois mois, le test de l'anticoagulant lupique est resté positif, confirmant un syndrome des anticorps antiphospholipides (SAPL) post-vaccinal. L´association du livédo réticulaire au vaccin contre la COVID-19 ne doit pas être sous-estimée, et son degré de gravité reste à déterminer. Il est nécessaire de collecter davantage de données et de cas pour une analyse plus approfondie et détaillée.</AbstractText><CopyrightInformation>Copyright: Meryem Ouhaddach et al.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Livedo reticularis</Keyword><Keyword MajorTopicYN="N">adverse reaction</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>Les auteurs ne déclarent aucun conflit d´intérêts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39372698</ArticleId><ArticleId IdType="pmc">PMC11453108</ArticleId><ArticleId IdType="doi">10.11604/pamj.2024.49.9.31779</ArticleId><ArticleId IdType="pii">PAMJ-49-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Padron-Regalado E. Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains. Infect Dis Ther. 2020 Jun;9(2):255–274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177048</ArticleId><ArticleId IdType="pubmed">32328406</ArticleId></ArticleIdList></Reference><Reference><Citation>Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20;397(10275):671–681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7852454</ArticleId><ArticleId IdType="pubmed">33545094</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Dean NE. Understanding COVID-19 vaccine efficacy. Science. 2020 Nov 13;370(6518):763–765.</Citation><ArticleIdList><ArticleId IdType="pubmed">33087460</ArticleId></ArticleIdList></Reference><Reference><Citation>Manisty C, Otter AD, Treibel TA, McKnight Á, Altmann DM, Brooks T, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021 Mar 20;397(10279):1057–1058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7972310</ArticleId><ArticleId IdType="pubmed">33640038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 Dec 19;396(10267):1979–1993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674972</ArticleId><ArticleId IdType="pubmed">33220855</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogdanov G, Bogdanov I, Kazandjieva J, Tsankov N. Cutaneous adverse effects of the available COVID-19 vaccines. Clin Dermatol. 2021 May-Jun;39(3):523–531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8076732</ArticleId><ArticleId IdType="pubmed">34518015</ArticleId></ArticleIdList></Reference><Reference><Citation>Pai M, Chan B, Stall NM, Grill A, Ivers N, Maltsev A, et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT) following adenovirus vector COVID-19 vaccination. Science Table COVID-19 Advisory for Ontario. 2021 May 7;2(17):1–7.</Citation></Reference><Reference><Citation>Gutierrez J, Katan M, Elkind MSV. 36 - Collagen Vascular and Infectious Diseases. Accessed on 2nd Oct. 2021.</Citation></Reference><Reference><Citation>Khalil S, Hinds BR, Manalo IF, Vargas IM, Mallela S, Jacobs R. Livedo reticularis as a presenting sign of severe acute respiratory syndrome coronavirus 2 infection. JAAD Case Rep. 2020 Sep;6(9):871–874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7366974</ArticleId><ArticleId IdType="pubmed">32835045</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020 Jul;50(1):54–67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7225095</ArticleId><ArticleId IdType="pubmed">32415579</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>